Psychiatry in Medical Technology

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... SUSTENNA(TM) clinical trials, and a Professor of psychiatry and Neuroscience and Director of the ... (1) Keith SJ, Kanke JM. Journal of Clinical psychiatry 2003; 64:1308-15 (2) Robinson D, Woerner MG, ... Schizoaffective Disorder. Archives of General psychiatry 1999; 56:241-247 (3) Kane, JM. Review of ...

UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials

... Vice Chair and Professor in the Department of psychiatry at Innsbruck University Clinics in Austria, ... Hoschl, MD, DSc., FRCPsych., is Professor of psychiatry and department chairman at the Charles ... 2004, he has also served as a Professor of psychiatry at the University of P.J. Safarik in Kosice, ...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... said lead investigator Maurizio Fava, M.D., vice chair, department of psychiatry at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Researchers have speculated that the brain's ...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

... and Epidemiology and Associate Chair of Research for the Department of psychiatry at the University of California, San Francisco, and Chief of Geriatric psychiatry and Director of the Memory Disorders Clinic at the San Francisco VA ...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

... physicians and society, according to Steven Passik, Ph.D., Department of psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, ... Health Program in Seattle, and Ryan Caldeiro, M.D., Department of psychiatry and Behavioral Sciences at the University of Washington, Seattle , in ...

SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts

... panelists include: Chad Reissig, PhD, Postdoctoral Fellow, Department of psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine , ... York, NY Chad Reissig, PhD Postdoctoral Fellow, Department of psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine , ...

ADHD Genes Found; Known to Play Roles in Neurodevelopment

... The study appeared online today in the journal Molecular psychiatry . Unlike changes to single DNA bases, called SNPs or "snips," the ... Are Preferentially Associated with Neurodevelopmental Genes," Molecular psychiatry , published online, June 23, 2009. About The Children's Hospital of ...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

... Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with ... review of this topic published in 2007 in the American Journal of psychiatry . In the United States, approximately 7.8 percent of all school-aged ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

... control of their symptoms," remarked Dr. Peter J. Weiden, Professor of psychiatry and Director of the Psychotic Disorders Program at the University of ... with excellent tolerability," added Dr. Steven G. Potkin Professor of psychiatry and Human Behavior at the University of California at Irvine . "We also ...

Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder

... -- In a study published in The American Journal of psychiatry , a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., ... Medical Centre, Utrecht, the Netherlands; Gabriele Leverich, Biological psychiatry Branch, NIMH, NIH, Bethesda, Md.; Heinz Grune, M.D., Institute of ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... Implications for Primary Care Physicians. Prim Care Companion J Clin psychiatry 2007: 9(2):100-107 (2) Rynn M., et al. Efficacy and Safety of Duloxetine ... Anxiety Disorder: Three Independent Studies. The Journal of Clinical psychiatry 2007: 68(4):518-24 (6) Allgulander, C., et al. Pharmacotherapy of ...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

... falling asleep and staying asleep," says Maurizio Fava, MD, Professor of psychiatry at Harvard Medical School and Executive Vice Chair of the Department of psychiatry at Massachusetts General Hospital. "The extended release formulation ...

Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting

... or lack of efficacy," said Roger McIntyre, M.D., Associate Professor of psychiatry and Pharmacology at the University of Toronto and head of the Mood ... safety profile," said Steven Potkin, M.D., Professor, Department of psychiatry and Human Behavior, University of California, Irvine. "We are encouraged ...

Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

... time to relapse," said Professor Wolfgang Gaebel from the Department of psychiatry and Psychotherapy at the Heinrich-Heine University in Dusseldorf, Germany ... acting injectable, presented at the 161st Annual Meeting of the American psychiatry Association (APA), Washington, DC. ...

Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist

... of Pain Medicine, is Clinical Associate Professor in Anesthesiology and psychiatry and Director of Muscle Pain Research at the NYU School of Medicine. ... as Chief of the Pain Treatment Service in the departments of Medicine and psychiatry at New York's Lenox Hill Hospital for fourteen years. Dr. Marcus's ...

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

... was conducted at the Centre for Neuroimaging Sciences of the Institute of psychiatry at King's College London using functional magnetic resonance ... the project at the Centre for Neuroimaging Sciences at the Institute of psychiatry at King's College London stated: "We have clearly visualised not only a ...

New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly

... complain," said Belinda Borrelli, PhD, associate professor, department of psychiatry and human behavior, Brown Medical School and The Miriam Hospital. ... including Belinda Borelli, PhD, associate professor, department of psychiatry and human behavior, Brown Medical School and The Miriam Hospital; Jennifer ...

Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress

... at Annual Meeting of American Association for Geriatric psychiatry -- SAN FRANCISCO and ORLANDO, Fla., March 15 /PRNewswire-FirstCall/ ... topics at the annual meeting of the American Association for Geriatric psychiatry (AAGP) by Jeffrey Cummings, M.D., the Augustus Rose Professor of Neurology ...

Vanda Presents Phase III Iloperidone Efficacy Data

... principal investigator of the Phase III study and Assistant Professor of psychiatry at the University of Florida. "Iloperidone's combination of comparable ... Peter Weiden, M.D., Director of the Psychosis Program of the Department of psychiatry at the University of Illinois at Chicago and one of the leading experts on ...

FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder

... (1) Nierenberg, A. Long-Term Management of Chronic Depression. J Clin psychiatry 2001; 62 (Suppl 6):17-20. (2) Perahia DG, et al. 2006. Duloxetine in the ... depressive disorder: double-blind placebo-controlled study. Br J psychiatry 188:346-353. (Logo: ...

Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration

... specialty biopharmaceutical company, today announced that Biological psychiatry published the results of a study showing VYVANSE(TM) (lisdexamfetamine ... to patient," said Ann S. Childress, M.D., President of the Center for psychiatry and Behavioral Medicine, Inc. in Las Vegas, Nev. "This prodrug stimulant ...

SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia

... results of the clinical trial appear in the November issue of the journal psychiatry 2007.(3) "Today's FDA approval helps address the need for longer-term ... randomized, placebo-controlled trial in clinically stable patients. psychiatry 2007. 2007; 4(11):34-50. (4) American Psychiatric Association. Diagnostic ...

A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities

... behavior,'" said Robert Findling, M.D., lead author and professor of psychiatry at Case Western Reserve University and director of the division of child and adolescent psychiatry at University Hospitals Case Medical Center. "There was a notable ...

New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression

... pain: a blind comparison of DSM-III diagnoses." American Journal of psychiatry 1991; 148:1721-1726. (2) Arnold LM, et al. "Comorbidity of fibromyalgia and psychiatric disorders." Journal of Clinical psychiatry 2006; 67:1219-1225. (3) American College of Rheumatology Web site - ...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

... observed in this study is comparable to drop out rates in typical depression studies. The results of this study are found in the May 2009 issue of psychiatry (Edgemont) (Volume 6, Number 5) ( www.psychiatrymmc.com ). Major depressive disorder (MDD) is a common mental illness often characterized by a ...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

... is a national leader in the research and treatment of diabetes, headaches , obesity, cough and sleep disorders , geriatrics and geriatric psychiatry , neurology and neurosurgery , adolescent and family medicine , HIV/AIDS and social and environmental medicine, among many other ...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... deCODE genetics, the National-University Hospital in Reykjavik, the University of Aberdeen , the Ravenscraig Hospital in Greenock, the Institute of psychiatry at King's College London, the National Public Health Institute in Helsinki, the Ludwig Maximilians University and GlaxoSmithKline's Genetic Research ...

Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases

... controlling movement disorders," according to the review, written by Susannah Tye, Ph.D., Mark Frye, M.D. , from the Mayo Clinic Department of psychiatry and Psychology , and Kendall Lee, M.D., Ph.D. , Mayo Clinic Department of Neurosurgery . "It now is being investigated for hard-to-treat ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... 2005 Jun;62(6):617-27. (8) Mauricio Tohen et al. (2007). Olanzapine versus Placebo in the Treatment of Adolescents with Bipolar Mania. Am J psychiatry 2007, 164: 1547-1556 (9) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, pg. 385. Available at: ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical psychiatry . This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single ...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

... at 5.3 percent (with large variability), according to a comprehensive systematic review of this topic published in 2007 in the American Journal of psychiatry . In the United States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed ...

Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia

... of efficacy, safety and tolerability so that the symptoms can be stabilized and effectively treated," said Henry Nasrallah, M.D., professor of psychiatry and neuroscience and director of the schizophrenia research program at the University of Cincinnati College of Medicine. "Lurasidone has the ...

FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults

... Notes for editors: About Long-acting Injectable Antipsychotic Medications The World Federation of Societies of Biological psychiatry (WFSBP) guidelines state that poor or partial treatment compliance is a major problem in the long-term treatment of schizophrenia. Depot formulations ...

Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects

... Data Support Case for DNA-Guided Medicine in psychiatry HARTFORD, Conn., Dec. 9 /PRNewswire/ -- Results from a clinical study published in the current issue of the Future Medicine Group (London) ...

Stress-Related Disorders Affect Brain's Processing of Memory

... University of Udine in Italy, where the study is being conducted, and research fellow at the Brain Imaging Center of McLean Hospital, Department of psychiatry at Harvard Medical School in Boston. "Because traumatic memories are not adequately suppressed by the brain, they continue to interfere with the ...

Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease

... of Alzheimer's disease," said Dr. Marc Agronin, director of mental health services at the Miami Jewish Home and Hospital and associate professor of psychiatry at the University of Miami Miller School of Medicine. "Results from a previous study of Dimebon in Alzheimer's disease were encouraging, and we look ...

Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD

... with an oral ADHD stimulant treatment for up to 13 hours post-dose," said Ann C. Childress, MD, study investigator, president of the Center for psychiatry and Behavioral Medicine, Inc. in Las Vegas, and volunteer assistant professor of psychiatry at the University of Nevada School of Medicine in Las ...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

... SHPGY), the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical psychiatry found once-daily VYVANSE significantly improved Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults within the first week of ....

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

... results of this study showing improvement in abdominal pain and constipation are encouraging," said Douglas Drossman, M.D., Professor of Medicine and psychiatry at UNC School of Medicine, Division of Gastroenterology and Hepatology and Co-Director of the UNC Center for Functional GI & Motility Disorders, ...

Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings

... company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for ...